Daniel Moynihan joined ONO PHARMA USA, INC. as General Counsel in June 2022. As a member of the executive leadership team, Dan is responsible for developing solutions to legal and regulatory challenges by working closely as a strategic advisor and business partner to the President/CEO and senior team to ensure ONO PHARMA USA, INC.’s business practices, policies, and programs comply with all legal requirements. 

Dan has extensive legal and compliance experience at U.S. and global life sciences companies. In his previous positions, Dan has built legal and compliance teams and has established or revamped compliance programs to meet the evolving expectations of regulators. Before joining ONO PHARMA USA, INC., Dan held a range of senior Legal and Compliance roles at Spero Therapeutics, Oncopeptides, Akcea Therapeutics, MilliporeSigma, and EMD Serono. Dan previously was division counsel at EMD Serono, supporting the company’s oncology, endocrinology, and fertility franchises. Prior to EMD Serono, Dan practiced law in-house and in private practice in the U.S. and the U.K. 

Dan holds a J.D. from the Columbus School of Law at the Catholic University of America and a B.A. in Economics from the College of the Holy Cross and has been practicing law for more than 25 years.